Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1

Last updated: October 23, 2025
Sponsor: Bionomics Limited
Overall Status: Completed

Phase

3

Condition

Social Phobia

Anxiety Disorders

Mood Disorders

Treatment

225 mg BNC210

Placebo

Clinical Study ID

NCT06510504
BNC210.014
  • Ages 18-65
  • All Genders

Study Summary

The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • A current diagnosis of social anxiety disorder as defined in the DSM-5.

  • A Liebowitz Social Anxiety Scale total score of ≥60.

  • Suitable contraception use in line with protocol requirements.

  • Ability to swallow tablets.

Exclusion

Exclusion Criteria:

  • History of bipolar disorder, schizophrenia, schizoaffective disorder, psychoticdisorders, anorexia or bulimia, body dysmorphic disorder, PTSD, autism-spectrumdisorder or obsessive-compulsive disorder, or any other Axis I or II disorder whichis currently the primary focus of treatment over social anxiety disorder.

  • Hamilton Rating Scale for Depression score of ≥18.

  • Moderate or severe alcohol-use disorder, or any other substance-use disorder (anyseverity) in the past 12 months.

  • Use of psychotropic medications within 30 days of screening. Daily use ofbenzodiazepines within 90 days of screening.

  • Any clinically significant medical history or findings as determined by theInvestigator that could interfere with the objectives of the study or put theparticipant at risk.

Study Design

Total Participants: 370
Treatment Group(s): 2
Primary Treatment: 225 mg BNC210
Phase: 3
Study Start date:
August 06, 2024
Estimated Completion Date:
September 19, 2025

Study Description

This is a randomized, double-blind, placebo-controlled, 2-arm, parallel-group, multi-center study. Participants will attend a Screening Visit to confirm eligibility and then return to the clinic within 21 days to be randomized into the study. Randomized participants will receive a single dose of their allocated study medication (225 mg BNC210 or placebo) and approximately 1 hour later participate in a behavioral assessment task. After 1 week, a safety follow-up assessment will be conducted by phone/video conference.

Connect with a study center

  • AFFIRM-1 Study Site

    Encino, California 91316
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    La Jolla, California 92037
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Los Angeles, California 90025
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Oceanside, California 92056
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    San Diego, California 92103
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    San Jose, California 95124
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Sherman Oaks, California 91403
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Temecula, California 92591
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Encino 5346649, California 5332921 91316
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    La Jolla 5363943, California 5332921 92037
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Los Angeles 5368361, California 5332921 90025
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Oceanside 5378771, California 5332921 92056
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    San Diego 5391811, California 5332921 92103
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    San Jose 5392171, California 5332921 95124
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Sherman Oaks 5395244, California 5332921 91403
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Temecula 5401395, California 5332921 92591
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Jacksonville, Florida 32256
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Lauderhill, Florida 33319
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Miami Lakes, Florida 33016
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Orlando, Florida 32801
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Tampa, Florida 33607
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Jacksonville 4160021, Florida 4155751 32256
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Lauderhill 4161625, Florida 4155751 33319
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Miami Lakes 4164186, Florida 4155751 33016
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Orlando 4167147, Florida 4155751 32801
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Tampa 4174757, Florida 4155751 33607
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Decatur, Georgia 30030
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Decatur 4191124, Georgia 4197000 30030
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Boston, Massachusetts 02131
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Boston 4930956, Massachusetts 6254926 02114
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Princeton, New Jersey 08540
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Princeton 5102922, New Jersey 5101760 08540
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Brooklyn, New York 11229
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Brooklyn 5110302, New York 5128638 11229
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Charlotte, North Carolina 28211
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Charlotte 4460243, North Carolina 4482348 28211
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Media, Pennsylvania 19063
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Media 4559575, Pennsylvania 6254927 19063
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Austin, Texas 78737
    United States

    Site Not Available

  • AFFIRM-1 Study Site

    Austin 4671654, Texas 4736286 78737
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.